Executive Summary

The medical technology sector is entering a period of accelerated transformation, driven by structural shifts in pricing, care delivery, supply chains, and enabling technologies. For Europe, these forces present a dual challenge: maintaining competitiveness in a global market while adapting to regional healthcare and industrial policy priorities. Drawing on Clarivate's 'Medtech Trends to Watch in 2026,' this analysis explores five critical trends and their implications for European business strategy, investment, and innovation.

Introduction

Europe has long been a powerhouse in medical technology, home to global leaders in diagnostics, medical devices, and healthcare solutions. However, the industry is facing headwinds from pricing pressures, geopolitical volatility, and technological disruption. Understanding the trends shaping 2026 is essential for executives, policymakers, and investors seeking to navigate the evolving landscape.

Main Analysis

1. China's VBP Expansion: Redefining Global Market Economics

Mainland China's national volume-based procurement (VBP) program is no longer a localized policy. Its latest round introduces more sophisticated anchor-pricing logic and deeper price compression, while favoring domestic manufacturers. For European medtech multinationals, this means that China's pricing dynamics now influence expectations in other emerging markets and even in Europe's own procurement negotiations.

Strategic implications: European companies must reassess their portfolio strategies, potentially focusing on high-value differentiated products while exploring partnerships or local manufacturing to retain market access. The ripple effect could also pressure European health systems to demand lower prices, aligning with cost-containment policies.

2. Outpatient and ASC Settings: The Shift to Lower-Cost Care

The migration of procedures from hospitals to outpatient settings—accelerated by U.S. policy changes—is mirrored in Europe, where many countries are expanding day-surgery and community-based care. This shift alters the commercial models for device manufacturers, requiring value propositions that emphasize efficiency, safety, and patient throughput.

Strategic implications: European medtech firms must adapt product designs for portability and ease of use in non-hospital settings. Additionally, partnerships with ambulatory surgery centers and private providers could become key growth channels. This trend also aligns with Europe's focus on healthcare sustainability and reducing hospital backlogs.

3. Supply Chain Pressures: Reshaping Manufacturing Strategy

Global trade tensions, tariff exposure, and material costs are prompting medtech companies to diversify sourcing and adopt flexible multi-region manufacturing. Europe is at the forefront of this shift, with policy initiatives like the Critical Medicines Act and the European Chips Act emphasizing resilience. European medtech firms are under pressure to reshore production, enhance supply chain traceability, and invest in automation.

Strategic implications: Manufacturing footprint decisions are now strategic imperatives. Companies that invest in digital twins, additive manufacturing, and regional supplier networks will gain resilience. Public procurement rules that favor local production could reshape competitive advantage, but they may also raise costs—a trade-off for policymakers.

4. GLP-1 Therapies: Changing Care Pathways

The rapid adoption of GLP-1 receptor agonists for weight management is altering patient behavior and clinical pathways, with downstream effects on bariatric surgery, cardiovascular monitoring, and sleep apnea treatment. European health systems, facing rising obesity rates, are integrating these therapies, but cost and reimbursement vary across countries.

Strategic implications: Medtech companies exposed to metabolic-related devices must monitor procedure volumes and adapt. The trend also opens opportunities for digital health coaches and companion diagnostics. Investing in data analytics to understand patient trajectories is becoming essential.

5. Enabling Technologies: Platform-Based Competition

Robotics, imaging, navigation, and digital workflows are converging into integrated platform ecosystems. This is shifting competition from individual devices to comprehensive solutions that anchor service lines and generate data-driven insights. European firms are investing heavily in open platforms, but they face competition from U.S. and Asian giants.

Strategic implications: To remain competitive, European medtech companies must move beyond hardware-only models. Building partnerships with software developers, artificial intelligence (AI) specialists, and data platforms is critical. The EU's digital health policies, including the European Health Data Space, provide a framework for leveraging data while ensuring privacy.

Business Impact

These trends will affect European medtech in several ways:

• Corporate strategy: Companies will need to balance volume-based pricing in emerging markets with high-value innovation in Europe.
• Foreign direct investment: FDI in European medtech R&D may rise, particularly in digital health and sustainable manufacturing.
• Supply chains: Reshoring initiatives will attract investment in automated production and supplier ecosystems.
• Innovation: Platform-based competition will drive R&D expenditure in AI, robotics, and data analytics.
• Employment: Skills shifts toward software and system integration will require workforce reskilling.
• SMEs: Smaller firms may struggle to compete without partnerships or specialisation.

European Perspective

The European Union's regulatory and industrial policies are critical to shaping these trends. The Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR) could either enable or hinder innovation. The EU's industrial strategy aims to secure supply chains and promote digital transformation, but divergent national health policies create fragmentation.

As these trends unfold, cross-border cooperation will be key. The EU should encourage harmonised procurement and data-sharing frameworks to support platform-based innovation. Moreover, Europe must address pricing pressures by investing in clinical research and health technology assessment (HTA) to demonstrate value.

Future Outlook

Over the next three to five years, we expect:

• Consolidation: Medtech companies will increase M&A to acquire platform capabilities and expand geographic reach.
• Digital integration: AI-based clinical decision support and remote monitoring will become standard.
• Sustainability: Environmental, social, and governance (ESG) criteria will influence procurement and investment choices.
• Transatlantic competition: U.S. and Chinese players will intensify competition, prompting Europe to leverage its regulatory and data assets.

Conclusion

Europe's medtech industry must adapt to a changing global order. By understanding these five trends, companies can reposition their strategies, embrace platform-based innovation, and strengthen supply chain resilience. Policymakers, meanwhile, must create an enabling ecosystem that balances competitiveness, innovation, and patient access. The future is uncertain, but those who act strategically will lead.

Key Takeaways

• China's VBP is a marker of global pricing pressure; European firms must differentiate and localize.
• Ambulatory care expansion offers growth opportunities for cost-effective medical devices.
• Supply chain resilience is a strategic priority; invest in multi-regional manufacturing.
• GLP-1 therapies are reshaping metabolic care; monitor linked device markets.
• Platform-based competition will define market leadership; open partnerships are essential.

Sources

• Clarivate, 'Medtech Trends to Watch in 2026' (reference URL: https://clarivate.com/life-sciences-healthcare/blog/5-medtech-trends-to-watch-in-2026)